Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
Rhea-AI Summary
Liquidia Technologies (Nasdaq:LQDA) announced it will report its third quarter 2020 financial results on November 6, 2020. A conference call and webcast will follow on November 9, 2020, at 8:00 a.m. ET to discuss these results and provide a corporate update. The company focuses on developing novel products using its proprietary PRINT® technology, particularly LIQ861 for pulmonary arterial hypertension and LIQ865 for post-operative pain management. This strategy underlines their commitment to improving patient outcomes through advanced therapies.
Positive
- Focus on two key product candidates with worldwide commercial rights: LIQ861 and LIQ865.
- Utilizes proprietary PRINT® technology, enhancing safety and efficacy of therapies.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LQDA declined 27.71%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that third quarter 2020 financial results will be reported on Friday, November 6, 2020. The company will host a webcast and conference call on Monday, November 9, 2020 at 8:00 a.m. ET to discuss financial results and provide a corporate update.
The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 7617005. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
Media:
Michael Parks
Corporate Communications
484.356.7105
michael.parks@liquidia.com
FAQ
When will Liquidia report its third quarter 2020 financial results?
What time is Liquidia's conference call on November 9, 2020?
What are the main product candidates being developed by Liquidia?
What technology does Liquidia utilize in its drug development?
